Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nous-209 Vaccine in Lynch Syndrome
NCT05078866Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Nov 2022
- Primary completion
- Apr 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
A Phase 2 trial of NOUS-209 in Lynch syndrome (LS), sponsored by National Cancer Institute. Started Nov 2022; status: active, not recruiting.
02
Drugs
NOUS-209
03
Conditions
Lynch syndrome (LS)
Beyond the preview
Go deeper on NCT05078866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05078866.